The landmark No Surprises Act (NSA), signed into law in 2020, was designed as a shield for American patients, intended to end the era of “surprise” medical bills by effectively banning out-of-network balance billing. However, four years later, the legislation—specifically its Independent Dispute Resolution (IDR) mechanism—has become the epicenter of a high-stakes legal war between the nation’s largest health insurers and physician groups.
As the IDR process continues to churn through millions of claims, a pattern of litigation has emerged that threatens the law’s stability. While insurers argue that the system is being exploited by “middlemen” and providers to inflate costs, federal judges are increasingly signaling that the courtroom is not the place to settle these disputes.
The Core Conflict: Arbitration vs. Litigation
The No Surprises Act established a "baseball-style" arbitration process. When a health plan and an out-of-network provider cannot agree on a payment rate, they enter the IDR process: each side submits a final offer, and an independent third party selects one of the two amounts. This process was intentionally designed by Congress to be final, binding, and—crucially—outside the purview of the federal judiciary.
However, major insurers like Elevance, Aetna, and Blue Cross Blue Shield have attempted to bypass this restriction. In a series of lawsuits, these payers have alleged that various medical billing companies and physician groups are engaged in fraudulent "batching" of claims, accusing them of gaming the IDR system to secure inflated reimbursements.
The most recent flashpoint occurred in August, when U.S. District Judge Thomas Thrash Jr. dismissed a lawsuit brought by a Georgia subsidiary of Elevance against the billing company HaloMD. The insurer claimed that thousands of IDR disputes initiated in late 2024 amounted to a $6 million fraud. Judge Thrash refused to hear the case, ruling that the court lacked the jurisdiction to re-litigate awards that Congress explicitly protected from judicial review.
Chronology of a Legal Wave
The Georgia dismissal is not an isolated event; it is the latest in a mounting pile of legal failures for health plans attempting to use the courts to overturn IDR outcomes.
- April 2026: Anthem Blue Cross sees its California lawsuit against HaloMD dismissed outright.
- May 2026: Seven separate claims brought by Blue Cross Blue Shield of Texas against HaloMD and associated providers are thrown out by federal courts.
- May 2026: Aetna’s high-profile case against Radiology Partners in Florida meets the same fate, with the court declining to intervene in the arbitration results.
- August 2026: Judge Thrash dismisses the Elevance-HaloMD case in Atlanta, reinforcing the precedent that federal courts are not the proper venue for challenging the administrative outcomes of the NSA.
Wendell Potter, a former insurance industry executive turned industry critic, has noted that the consistency of these rulings is a clear signal. "Congress built IDR specifically to keep these disputes out of federal court," Potter wrote. "Insurers don’t get to use fraud and racketeering claims as a side door back in."
The Judicial Perspective: "Low-Ball" Offers vs. "Gold Rush" Claims
In his August opinion, Judge Thrash offered a scathing critique of the insurer’s logic. While he noted that the plaintiff had complained of losing 192 out of 228 IDR cases on a single day, he dismissed the idea of a “vast conspiracy.”
Instead, the judge suggested that the data was more consistent with a different reality: that health plans are systematically submitting "low-ball" offers to providers to maximize corporate profit. This interpretation mirrors the growing concern among policymakers that the IDR process has become a tug-of-war between two extremes—insurers attempting to suppress rates below market value and providers attempting to maximize reimbursement through the arbitration system.
Stacey Lee, a professor of law and ethics at Johns Hopkins University, argues that the legal failures of insurers stem from a lack of specific evidence. "A party claiming fraud must identify the specific misrepresentation, who made it, and how it affected the proceeding," Lee explains. "Aggregate allegations are not enough."
Supporting Data: An Overwhelmed System
The sheer volume of disputes reveals a system under extreme duress. According to an analysis of federal data by Modern Healthcare, from January through May 2026 alone, plans and providers filed 1.43 million IDR applications—a staggering 46% increase over the same period in 2025.
While the government and its contractors resolved 1.36 million of those cases, the backlog is persistent. The Congressional Budget Office (CBO) has reported that in these IDR cases, providers prevail approximately 80% of the time, often securing payments up to five times the average contracted rate.
This high win rate for providers is the primary catalyst for insurer frustration. However, providers argue that these numbers reflect a systemic failure by insurers to pay fair rates from the outset, forcing physicians to turn to arbitration just to receive compensation that covers the cost of care.
Official Responses and Industry Polarization
The battle lines are sharply drawn, with both sides lobbying for aggressive federal intervention.
The Insurer Position
America’s Health Insurance Plans (AHIP), the leading trade group for the industry, maintains that the system is broken. Chris Bond, an AHIP spokesperson, stated: "Abuse of the No Surprises Act by some out-of-network providers and IDR middlemen is adding billions in wasteful spending and raising healthcare costs for everyone. Policy action is needed to put an end to this gold rush and protect consumers from this unconscionable price gouging."
The Provider Position
Conversely, physician groups—including the American Medical Association (AMA) and the American College of Emergency Physicians—have accused insurers of bad-faith tactics. They point to "problematic conduct" where insurers lose arbitration cases and then delay payment or reprocess claims to avoid paying the awarded amounts.
A recent survey found that 22% of IDR awards owed to clinicians in 2023, and 11% in 2024, remained unpaid. "Providers are being forced to play by the rules of the law, while payers are treating the law as optional," one representative noted.
Implications: The Reality of "Private Right of Action"
The legal landscape is further complicated by the fact that neither party has found an easy way to enforce the law’s provisions through the courts.
As Stacey Lee points out, the Fifth Circuit previously held that the No Surprises Act does not create a "standalone private right of action" to enforce arbitration awards. Because the Supreme Court declined to review that ruling, providers are left in a precarious position: if an insurer simply refuses to pay an IDR award, the provider has limited recourse outside of the administrative complaint process, which critics argue is slow and toothless.
What Lies Ahead?
The implications of this legal stalemate are profound:
- Administrative Burden: As long as the volume of IDR cases continues to rise, the federal government will struggle to manage the administrative load. The 46% increase in applications suggests the system may soon hit a breaking point.
- Regulatory Reform: With the courts refusing to act as a "side door" for litigation, the pressure will shift entirely to the Department of Health and Human Services (HHS) and Congress. We can expect increased calls for stricter enforcement of payment timelines and, potentially, legislative tweaks to the IDR process to discourage excessive filing.
- Market Distortions: The "asymmetry" noted by legal experts remains the fundamental flaw. Payers still control the flow of money, and providers still lack an efficient mechanism to force payment on won awards.
Conclusion
The No Surprises Act has succeeded in its primary goal: patients are largely insulated from the trauma of surprise medical bills. However, the secondary goal—creating a fair, efficient marketplace for reimbursement—remains elusive.
As the courts continue to dismiss insurer attempts to re-litigate arbitration results, the "lawsuit wave" appears to be cresting. Whether this leads to a new era of regulatory stability or a legislative overhaul remains to be seen. What is clear, however, is that the current status quo—marked by millions of disputes, billions in legal and administrative costs, and an impasse over unpaid awards—is unsustainable for both the insurance industry and the nation’s healthcare providers. The resolution to the "surprise billing" problem has, ironically, become the source of the next great surprise in American healthcare.
